BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24225180)

  • 1. SELDI-TOF analysis of glioblastoma cyst fluid is an approach for assessing cellular protein expression.
    Hoelscher M; Richter N; Melle C; von Eggeling F; Schaenzer A; Nestler U
    Neurol Res; 2013 Dec; 35(10):993-1001. PubMed ID: 24225180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of protein biomarkers in Dupuytren's contracture using surface enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS).
    O'Gorman D; Howard JC; Varallo VM; Cadieux P; Bowley E; McLean K; Pak BJ; Gan BS
    Clin Invest Med; 2006 Jun; 29(3):136-45. PubMed ID: 17058431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS).
    Hong H; Dragan Y; Epstein J; Teitel C; Chen B; Xie Q; Fang H; Shi L; Perkins R; Tong W
    BMC Bioinformatics; 2005 Jul; 6 Suppl 2(Suppl 2):S5. PubMed ID: 16026602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classification of pancreatic cystic lesions using SELDI-TOF mass spectrometry.
    Scarlett CJ; Samra JS; Xue A; Baxter RC; Smith RC
    ANZ J Surg; 2007 Aug; 77(8):648-53. PubMed ID: 17635277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors.
    Ricolleau G; Charbonnel C; Lodé L; Loussouarn D; Joalland MP; Bogumil R; Jourdain S; Minvielle S; Campone M; Déporte-Fety R; Campion L; Jézéquel P
    Proteomics; 2006 Mar; 6(6):1963-75. PubMed ID: 16470659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles.
    Cadron I; Van Gorp T; Amant F; Vergote I; Moerman P; Waelkens E; Daemen A; Van De Plas R; De Moor B; Zeillinger R
    Anticancer Res; 2009 Apr; 29(4):1039-45. PubMed ID: 19414343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer.
    Wang Q; Shen J; Li ZF; Jie JZ; Wang WY; Wang J; Zhang ZT; Li ZX; Yan L; Gu J
    BMC Cancer; 2009 Aug; 9():287. PubMed ID: 19689818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyst Fluid From Cystic, Malignant Brain Tumors: A Reservoir of Nutrients, Including Growth Factor-Like Nutrients, for Tumor Cells.
    Dahlberg D; Struys EA; Jansen EE; Mørkrid L; Midttun Ø; Hassel B
    Neurosurgery; 2017 Jun; 80(6):917-924. PubMed ID: 28327992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fine-needle aspiration in PreservCyt: a novel and reproducible method for possible ancillary proteomic pattern expression of breast neoplasms by SELDI-TOF.
    Fowler LJ; Lovell MO; Izbicka E
    Mod Pathol; 2004 Aug; 17(8):1012-20. PubMed ID: 15195106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker.
    Chen L; Ho DW; Lee NP; Sun S; Lam B; Wong KF; Yi X; Lau GK; Ng EW; Poon TC; Lai PB; Cai Z; Peng J; Leng X; Poon RT; Luk JM
    Ann Surg Oncol; 2010 Sep; 17(9):2518-25. PubMed ID: 20354800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saliva analysis by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) in orthodontic treatment: first pilot study.
    Ciavarella D; Mastrovincenzo M; D'Onofrio V; Chimenti C; Parziale V; Barbato E; Lo Muzio L
    Prog Orthod; 2011 Nov; 12(2):126-31. PubMed ID: 22074837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of ApoC1, LuzP6, C12orf75 and OCC-1 in cystic glioblastoma using MALDI-TOF mass spectrometry, immunohistochemistry and qRT-PCR.
    Evangelou P; Groll M; Oppermann H; Gaunitz F; Eisenlöffel C; Müller W; Eschrich K; Schänzer A; Nestler U
    Med Mol Morphol; 2019 Dec; 52(4):217-225. PubMed ID: 31006040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Screening of differentially expressed proteins associated with directional highly lymphatic metastasis in ovarian carcinoma cell lines using SELDI-TOF-MS technology].
    Guan X; Li DR; Wang Q; Li L; Ruan HY; Zhang W
    Ai Zheng; 2008 Nov; 27(11):1155-60. PubMed ID: 19000445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surface-enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS): a new proteomic urinary test for patients with urolithiasis.
    Cadieux PA; Beiko DT; Watterson JD; Burton JP; Howard JC; Knudsen BE; Gan BS; McCormick JK; Chambers AF; Denstedt JD; Reid G
    J Clin Lab Anal; 2004; 18(3):170-5. PubMed ID: 15103681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SELDI-TOF-MS of saliva: methodology and pre-treatment effects.
    Schipper R; Loof A; de Groot J; Harthoorn L; Dransfield E; van Heerde W
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Feb; 847(1):45-53. PubMed ID: 17070117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of surface enhanced laser desorption/ionization-time of flight mass spectrometry (SELDI-TOF MS) to study protein expression in a rat model of cocaine withdrawal.
    Geng T; Seitz PK; Thomas ML; Xu B; Soman KV; Kurosky A; Luxon BA; Cunningham KA
    J Neurosci Methods; 2006 Nov; 158(1):1-12. PubMed ID: 16766040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of serum SELDI proteomic patterns in diagnosis of lung cancer.
    Yang SY; Xiao XY; Zhang WG; Zhang LJ; Zhang W; Zhou B; Chen G; He DC
    BMC Cancer; 2005 Jul; 5():83. PubMed ID: 16029516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker discovery using SELDI-TOF protein chip technology.
    Lehr S
    Arch Physiol Biochem; 2010; 116(4-5):157. PubMed ID: 20839924
    [No Abstract]   [Full Text] [Related]  

  • 19. MALDI/SELDI protein profiling of serum for the identification of cancer biomarkers.
    Cazares LH; Diaz JI; Drake RR; Semmes OJ
    Methods Mol Biol; 2008; 428():125-40. PubMed ID: 18287771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct-tissue SELDI-TOF mass spectrometry analysis: a new application for clinical proteomics.
    Bouamrani A; Ternier J; Ratel D; Benabid AL; Issartel JP; Brambilla E; Berger F
    Clin Chem; 2006 Nov; 52(11):2103-6. PubMed ID: 16990423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.